Identification and characterization of human PCDH10 gene promoter

Gene

Volumn 475, Issue 1, 2011, Pages 49-56

  Li, Zesong ^a   Xie, Jun ^a   Li, Wenjie ^a   Tang, Aifa ^a   Li, Xianxin ^a   Jiang, Zhimao ^a   Han, Yonghua ^a   Ye, Jiongxian ^a   Jing, Jie ^b   Gui, Yaoting ^a   Cai, Zhiming ^a,c  

^a PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SHENZHEN UNIVERSITY   (China)

Author keywords

CAAT box; NF Y; Sp1 Sp3; TATA less promoter

Indexed keywords

BINDING PROTEIN; CCAAT BINDING FACTOR; GT BOX BINDING PROTEIN; MITHRAMYCIN; MITHRAMYCIN A; PROTOCADHERIN 10; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL LINE; CONTROLLED STUDY; DELETION MUTANT; GENE ACTIVITY; GENE EXPRESSION; GENETIC CONSERVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; REPORTER GENE; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; CADHERINS; CCAAT-BINDING FACTOR; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA MUTATIONAL ANALYSIS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR;

EID: 79952004216     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gene.2011.01.001     Document Type: Article

References (43)

1. Angst B.D., Marcozzi C., Magee A.I. The cadherin superfamily: diversity in form and function. J. Cell Sci. 2001, 114:629-641.
2. Blume S.W., Snyder R.C., Ray R., Thomas S., Koller C.A., Miller D.M. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J. Clin. Invest. 1991, 88:1613-1621.
3. Carninci P., et al. Genome-wide analysis of mammalian promoter architecture and evolution. Nat. Genet. 2006, 38:626-635.
4. Cheung H.H., Lee T.L., Davis A.J., Taft D.H., Rennert O.M., Chan W.Y. Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br. J. Cancer 2010, 102:419-427.
5. Frank M., Kemler R. Protocadherins. Curr. Opin. Cell Biol. 2002, 14:557-562.
6. Gory S., Dalmon J., Prandini M.H., Kortulewski T., de Launoit Y., Huber P. Requirement of a GT box (Sp1 site) and two Ets binding sites for vascular endothelial cadherin gene transcription. J. Biol. Chem. 1998, 273:6750-6755.
7. Grabe N. AliBaba2: context specific identification of transcription factor binding sites. In Silico Biol. 2002, 2:S1-S15.
8. Hagen G., Muller S., Beato M., Suske G. Cloning by recognition site screening of two novel GT box binding proteins: a family of Sp1 related genes. Nucleic Acids Res. 1992, 20:5519-5525.
9. Hardison R.C. Conserved noncoding sequences are reliable guides to regulatory elements. Trends Genet. 2000, 16:369-372.
10. Hirayama T., Yagi T. The role and expression of the protocadherin-alpha clusters in the CNS. Curr. Opin. Neurobiol. 2006, 16:336-342.
11. Imoto I., et al. Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res. 2006, 66:4617-4626.
12. Knudsen S. Promoter2.0: for the recognition of PolII promoter sequences. Bioinformatics 1999, 15:356-361.
13. Le Mee S., Fromigue O., Marie P.J. Sp1/Sp3 and the myeloid zinc finger gene MZF1 regulate the human N-cadherin promoter in osteoblasts. Exp. Cell Res. 2005, 302:129-142.
14. Liu Y.N., Lee W.W., Wang C.Y., Chao T.H., Chen Y., Chen J.H. Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene 2005, 24:8277-8290.
15. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
16. Luan X., Ito Y., Zhang Y., Diekwisch T.G. Characterization of the mouse CP27 promoter and NF-Y mediated gene regulation. Gene 2010, 460:8-19.
17. Mantovani R. The molecular biology of the CCAAT-binding factor NF-Y. Gene 1999, 239:15-27.
18. Mantovani R., Li X.Y., Pessara U., Hooft van Huisjduijnen R., Benoist C., Mathis D. Dominant negative analogs of NF-YA. J. Biol. Chem. 1994, 269:20340-20346.
19. Melton D.W., Konecki D.S., Brennand J., Caskey C.T. Structure, expression, and mutation of the hypoxanthine phosphoribosyltransferase gene. Proc. Natl Acad. Sci. USA 1984, 81:2147-2151.
20. Morrow E.M., et al. Identifying autism Loci and genes by tracing recent shared ancestry. Science 2008, 321:218-223.
21. Muckenfuss H., et al. Sp1 and Sp3 regulate basal transcription of the human APOBEC3G gene. Nucleic Acids Res. 2007, 35:3784-3796.
22. Narayan G., Scotto L., Neelakantan V., Kottoor S.H., Wong A.H., Loke S.L., Mansukhani M., Pothuri B., Wright J.D., Kaufmann A.M., Schneider A., Arias-Pulido H., Tao Q., Murty V.V. Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer. Genes Chromosomes Cancer 2009.
23. Nollet F., Kools P., van Roy F. Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members. J. Mol. Biol. 2000, 299:551-572.
24. Pallai R., Simpkins H., Chen J., Parekh H.K. The CCAAT box binding transcription factor, nuclear factor-Y (NF-Y) regulates transcription of human aldo-keto reductase 1C1 (AKR1C1) gene. Gene 2010, 459:11-23.
25. Purvis T.L., et al. Transcriptional regulation of the Alstrom syndrome gene ALMS1 by members of the RFX family and Sp1. Gene 2010, 460:20-29.
26. Safe S., Abdelrahim M. Sp transcription factor family and its role in cancer. Eur. J. Cancer 2005, 41:2438-2448.
27. Sano K., Tanihara H., Heimark R.L., Obata S., Davidson M., St John T., Taketani S., Suzuki S. Protocadherins: a large family of cadherin-related molecules in central nervous system. EMBO J 1993, 12:2249-2256.
28. Sun F., Xie Q., Ma J., Yang S., Chen Q., Hong A. Nuclear factor Y is required for basal activation and chromatin accessibility of fibroblast growth factor receptor 2 promoter in osteoblast-like cells. J. Biol. Chem. 2009, 284:3136-3147.
29. Tang S., et al. Evidence that Sp1 positively and Sp3 negatively regulate and androgen does not directly regulate functional tumor suppressor 15-lipoxygenase 2 (15-LOX2) gene expression in normal human prostate epithelial cells. Oncogene 2004, 23:6942-6953.
30. Uemura M., Nakao S., Suzuki S.T., Takeichi M., Hirano S. OL-protocadherin is essential for growth of striatal axons and thalamocortical projections. Nat. Neurosci. 2007, 10:1151-1159.
31. van Wageningen S., Nikoloski G., Vierwinden G., Knops R., van der Reijden B.A., Jansen J.H. The transcription factor nuclear factor Y regulates the proliferation of myeloid progenitor cells. Haematologica 2008, 93:1580-1582.
32. Waha A., Guntner S., Huang T.H., Yan P.S., Arslan B., Pietsch T., Wiestler O.D. Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia 2005, 7:193-199.
33. Wang K.H., Liu H.W., Lin S.R., Ding D.C., Chu T.Y. Field methylation silencing of the protocadherin 10 gene in cervical carcinogenesis as a potential specific diagnostic test from cervical scrapings. Cancer Sci. 2009.
34. Wolverton T., Lalande M. Identification and characterization of three members of a novel subclass of protocadherins. Genomics 2001, 76:66-72.
35. Yagi T. Clustered protocadherin family. Dev. Growth Differ. 2008, 50(Suppl 1):S131-S140.
36. Yagi T., Takeichi M. Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. Genes Dev. 2000, 14:1169-1180.
37. Ying J., et al. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br. J. Haematol. 2007, 136:829-832.
38. Ying J., et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 2006, 25:1070-1080.
39. Yu B., Datta P.K., Bagchi S. Stability of the Sp3-DNA complex is promoter-specific: Sp3 efficiently competes with Sp1 for binding to promoters containing multiple Sp-sites. Nucleic Acids Res. 2003, 31:5368-5376.
40. Yu B., et al. High-resolution melting analysis of PCDH10 methylation levels in gastric, colorectal and pancreatic cancers. Neoplasma 2010, 57:247-252.
41. Yu J., et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 2009, 136:640-651.
42. Yu J.S., et al. PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene 2008, 27:4657-4665.
43. Zou C., Huang W., Ying G., Wu Q. Sequence analysis and expression mapping of the rat clustered protocadherin gene repertoires. Neuroscience 2007, 144:579-603.